Entest Biomedical, Inc. and RenovoCyte, LLC Updates Progress on 10 Dog Pilot Study of "Universal Donor" Stem Cell Treatment for Canine Osteoarthritis
March 21, 2012 at 06:00 pm IST
Share
Entest Biomedical, Inc. and RenovoCyte, LLC announced they have treated 8 canine patients of a 10 dog pilot study utilizing Canine Endometrial Regenerative Cells (CERC) licensed from Medistem Inc. in the treatment of canine osteoarthritis. Previously, Entest announced the treatment of the first canine patient on November 18, 2011. Since that time Entest's McDonald Animal Hospital has treated 8 dogs in its 10 Dog Pilot Study with RenovoCyte. To date, all of the dogs participating in this study have shown dramatic improvement in their mobility and apparent reduction of pain. The CERC is a "universal donor" stem cell product that does not require matching with the recipient allowing for the generation of standardized products that can be delivered to the office of the veterinarian ready for injection. This is in stark contrast to current stem cell therapies utilized in veterinary applications which require the extraction, manipulation, and subsequent implantation of tissue from the animal being treated. CERC is the canine equivalent of Medistem's Endometrial Regenerative Cell (ERC). Medistem was recently granted approval from the FDA to initiate a clinical trial in human patients using its ERCs.
Entest Group, Inc., formerly Entest Biomedical, Inc., is engaged in the business combination with an unidentified company. The Company has not entered into any definitive agreement with any party, nor have there been any specific discussions with any potential business combination candidate regarding business opportunities for the Company.